myTomorrows has raised $29 million from Avego to support its global expansion and further develop its AI platform connecting patients, physicians and industry partners with pre-approval treatments.

The Amsterdam-based health technology company said the funding will help scale access to clinical trials and expanded access programmes (EAPs) for patients with conditions lacking approved therapies. myTomorrows aims to address one of healthcare’s most pressing challenges — bridging the gap between scientific innovation and patient access.

The new investment will strengthen collaborations with industry partners to accelerate trial recruitment, enhance real-world data capabilities and support regulatory insight.

Michel van Harten, chief executive of myTomorrows, said: “This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow’s therapies. Avego’s extensive expertise in life sciences, particularly BioPharma, will be instrumental as we scale our platform and broaden our impact across the global health landscape.”

James Flexner, managing partner at Avego, added: “We believe myTomorrows is uniquely positioned to remove barriers for patients and providers while serving as an essential partner to BioPharma.”

Since its founding in 2012, myTomorrows has supported more than 16,900 patients in over 133 countries. Its AI-powered platform connects patients, physicians and trial sites, offering expert navigation services, treatment matching and streamlined access to both clinical trials and EAPs.

For BioPharma partners, the company provides clinical trial recruitment and real-world data collection, while trial sites benefit from a unified referral management system that enables real-time status updates.

myTomorrows said its goal is to become the default gateway for pre-approval therapies, building infrastructure for a new era of treatment access defined by AI, adaptive regulation and greater patient empowerment.